Background/Aim: Women with advanced ovarian carcinoma are less likely to receive platinum-based chemotherapy and surgery due to a greater risk of cytotoxicity and poorer outcomes. We attempted to improve a promising therapy against ovarian cancer by using a combination of dihydroartemisinin (DHA) and curcumin (Cur). Methods: Human ovarian cancer SKOV3 cells were treated with DHA, Cur alone, or a combination of both. The viability of SKOV3 cells was measured by Cell Counting Kit-8 (CCK-8) and a colony formation assay. The cell cycle and apoptosis of SKOV3 cells were monitored by flow cytometry. The mRNA and protein expression levels of target genes were respectively examined by qRT-PCR and western blot. The biological effects of miR-124 on midkine (MK) were verified by a luciferase activity analysis. Results: Combined treatment of DHA and Cur synergistically decreased cell viability, arrested cell cycle, and promoted apoptosis in SKOV3 cells. Moreover, it significantly attenuated the expression of oncogene MK and synergistically upregulated the expression of miR-124. Furthermore, miR-124 was verified to bind directly to the 3ʹ-untranslated region of MK mRNA, resulting in mRNA degradation and reduced MK protein levels. The combination of DHA with Cur significantly inhibited tumor growth in xenograft nude mice without obvious toxicity. Conclusion: Co-treatment with DHA and Cur exhibited a synergistic anti-tumor effect on SKOV3 cells both in vitro and in vivo.
Dihydroartemisinin and Curcumin

Introduction
Ovarian cancer is the seventh most common cancer among women and one of the most lethal female cancers worldwide. In current clinical practice, chemotherapy and surgery, and sometimes radiotherapy, are considered standard treatments for ovarian cancer, regardless of the cancer subtype [1] . The major reason for treatment failure is uncertain. It may be due to a lack of early detection, inappropriate chemotherapy, geriatric syndromes, undertreatment, or other reasons [2, 3] . There is therefore a pressing need to explore a promising strategy to optimize the treatment of ovarian cancer in older patients.
Dihydroartemisinin (DHA), a derivative and active metabolite of artemisinin, is isolated from the Chinese medicinal herb, Artemisia annua. It has been recommended by the World Health Organization as a first line anti-malarial therapy [4] . In addition to its potent anti-malarial activity, emerging studies have shown that DHA may also be a potential chemopreventive drug, exhibiting strong antitumor activity in various human cancer cells by blocking cell proliferation [5] , arresting cell cycle [6] , promoting apoptosis [7] , and inhibiting angiogenesis and metastasis [8, 9] . In addition, DHA can potentiate the anticancer effect of chemotherapeutic agents and photodynamic therapy to induce cell apoptosis in various kinds of cancers [10] [11] [12] [13] . Curcumin (Cur) is a well-known dietary polyphenol extracted from the rhizome of the plant Curcuma longa. Multiple studies have suggested that Cur is a promising agent possessing excellent anti-inflammation, antioxidation and anticancer activities [14] [15] [16] [17] [18] . Besides its capacities to directly inhibit cell viability, induce apoptosis, and inhibit migration and metastases in vitro and in vivo, Cur could synergistically enhance the radio-sensitivity and anticancer effect of some chemotherapeutic agents through regulation of diverse non-coding RNAs in different cancers, including ovarian cancer [19] [20] [21] . These data suggest that DHA and Cur may be potential alternative medicines for the clinical treatment of ovarian cancer.
Midkine (MK), a heparin-binding growth factor, is significantly overexpressed in multifarious cancers compared with healthy normal samples [22] . In general, MK expression frequently elevates with advancing tumor stage and closely correlates with poor prognosis. It was reported that blockade of MK suppressed tumorigenesis and tumor development, and an antisense oligonucleotide targeted to MK likewise repressed tumor formation in nude mice [23, 24] . We previously also found that MK was highly expressed in the gastric tumor tissues of Chinese patients and patients with malignant effusions [25, 26] . Both siRNA targeting MK gene and the conjugate (a single-chain variable fragment against human MKDoxorubicin) inhibited gastric cancer cell growth and induced apoptosis [27, 28] . MK is therefore an attractive molecular target for cancer therapy.
Although DHA and Cur, as effective traditional Chinese medicines, both have excellent anticancer properties without any side effects, the combination effect of these compounds are rarely investigated. In this study, we showed that a combination of DHA and Cur synergistically decreased cell viability, arrested cell cycle and induced cell apoptosis in ovarian cancer SKOV3 cells. The cytotoxicity of DHA and Cur co-treatment was verified to attribute to the upregulation of miR-124 by targeting MK. Moreover, the combination treatment also made an important contribution to the antitumor effects without any toxicity in vivo. Taken together, these data showed that the combination of DHA and Cur may be a potent anticancer strategy for the treatment of ovarian cancer, especially in older patients.
Materials and Methods
Cell culture and drugs
The human ovarian cancer cell line SKOV3 was cultured in complete Dulbecco's Modified Eagle's Medium (DMEM)/F12 (Gibco, Life Technologies) with antibiotics (penicillin 100 U/ml, streptomycin 0.1 mg/ml, Invitrogen, Life Technologies) and 10% fetal bovine serum (FBS, Life Technologies) at 37 °C in a 5% CO 2 incubator. Cells were grown in monolayer and passaged routinely 2~3 times a week. 
Cell viability
The cell viability of SKOV3 was assessed using the Cell Counting Kit-8 (CCK-8) assay. Briefly, cells were seeded at a density of 5 × 10 3 cells per well in 96-well plates in quadruplicate and incubated in a 5% CO 2 atmosphere at 37 °C before treatment with drugs. After removing the culture medium, cells were treated with fresh medium containing different concentrations of DHA and/ or Cur (Sigma-Aldrich, dissolved in DMSO) and incubated for 24 h or 48 h. The supernatants were then discarded; fresh medium was incorporated with 10 μl of WST-8 reagent from CCK-8 (Dojindo, Kumamoto, Japan), and the cells were incubated for another 4 h at 37 °C. Absorbance was determined with a multi-well spectrophotometer (BioTek, VT, USA) at 450 nm. Data were analyzed by CompuSyn software with combination index (CI) values based on the median-effect principle and ChouTalalay equation to determine whether the combination was synergistic [29] . The combined effects of the two compounds can be summarized as follows: CI < 1, CI = 1, CI > 1 indicate synergistic, additive and antagonistic effects, respectively.
Isolation of total RNA and Quantitative RT-PCR
Total RNA was extracted from collected cells using TRIzol (Invitrogen, Carlsbad, CA, USA). Both miRNA and mRNA were then reverse transcribed to cDNA using the Revert AidTM First Strand cDNA Synthesis Kit (Fermentas) according to the instructions. The expression of mature miRNAs and potential target genes, with U6 or GAPDH serving as an endogenous control, were measured by qRT-PCR with SYBR Green PCR Kit (Bio-Rad) on the Applied Biosystems StepOne-Plus Real-Time PCR System (Applied Biosystems, Foster City, CA). The relative expression ratio of target genes was calculated by the 2 -ΔΔCT method; the sequences of qRT-PCR primers are provided in Table 1 .
Flow cytometric analysis
For cell cycle analysis, SKOV3 cells were harvested, washed twice with cold phosphate-buffered saline (PBS), and were fixed with ice-cold 70% ethanol overnight at -20 °C. Cells were then washed twice with PBS and incubated with 0.2 ml PBS containing 50 μg/ml propidium iodide (PI), 0.1% Triton X-100 and 50 μg/ ml DNase-free RNase (Sigma-Aldrich, St. Louis, MO, USA) at room temperature in the dark for 15 min. After detection by FACS Calibur FCM (BD, CA, USA), data were analyzed using Mod Fit LT 3.0 software.
Cell apoptosis analysis was conducted by Annexin V-FITC analysis. Briefly, cells were seeded for 24 h and then treated with DHA and/or Cur for another 48 h. To measure Caspase 3 activity, cells were pretreated with Caspase 3 inhibitor Ac-DEVD-CHO 50 μM for 30 min. The cells were then harvested, washed twice with PBS, stained with Annexin V-FITC and PI in binding buffer, and detected by FCM after 15 min incubation at room temperature in the dark. The early apoptotic cells (Annexin V positive only) and late apoptotic cells (Annexin V and PI positive) were quantified.
Western blotting (WB)
Cells with various treatments were lysed in an ice-cold RIPA lysis buffer (Beyotime), centrifuged to collect supernatants, and quantitated by BCA Protein Quantification Kit (Vazyme Biotech Co., Ltd.). Equal amounts of proteins were then fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred to PVDF membrane (Bio-Rad, Hercules, CA), blocked in 5% BSA at room temperature for 1 h, and immunostained with primary antibodies (anti-Bax, Bcl-2, Caspase 3, Cyclin A, Cyclin B and CDK1 antibodies, Cell Signaling Technologies; anti-β-actin antibody, Bioworld; anti-MK antibody, Abcam) at 4 °C overnight and secondary antibodies (Thermofisher Scientific) at room temperature for 1 h. The expression of proteins was then visualized with ECL Plus western blotting detection reagents (Millipore, USA).
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ELISA assay for MK in cell culture media MK in cell culture supernatant was measured via an enzyme-linked immunosorbent assay (ELISA) using a commercial kit (Abcam) according to the manufacturer's instructions. Briefly, after SKOV3 cells were treated with DHA, Cur, or both for 48 h, cell culture media were collected and centrifuged at 2, 000 × g for 10 min to remove debris. Aliquots of 50 µl diluted samples were then measured according to the manufacturer's instructions, and the final data were obtained from the detected OD at 450 nm.
Luciferase activities analysis
For luciferase activity analysis, human 293-T cells were cultured in 24-well plates and transfected with 0.5 μg of either wide-type or mutant psiCHECK™2 Vector containing both firefly luciferase and renilla luciferase, together with miR-NC, miR-124 mimic, inhibitor-NC and miR-124 inhibitor (RiboBio, Guangzhou, China). Transfection was performed using Lipofectamine 3000 reagent (Invitrogen Life Technologies). The cell lysates were analyzed for luciferase activity 20 h post-transfection by the Dual Luciferase Reporter Assay (Promega) according to the manufacturer's instructions.
Nude mice xenograft tumor assay
For the nude mice xenograft tumor assay, 2 × 10 7 SKOV3 cells were suspended in 100 μl of sterile PBS were injected subcutaneously into the right flank of female BALB/c nude mice (4-6 weeks). When tumors reached an average size of 50 mm 
Statistical analysis
All experiments were repeated at least three times. One-way ANOVA followed by the Student's t-test were used to analyze the statistical significance among groups, and P < 0.05 was considered statistically significant. Graphics were built using GraphPad prism software (www.graphpad.com).
Results
DHA and Cur synergistically decrease the cell viability of SKOV3
To determine the antitumor effects of DHA and Cur, SKOV3 cells were treated with DHA and/or Cur at different concentrations, viability was measured by the CCK-8 assay, and CI value was determined. As shown in Fig. 1A and B, SKOV3 cell viability was inhibited by DHA, Cur, and their combination in a dose-and time-dependent manner. Moreover, compared to single drug application, the combination of DHA and Cur at a constant ratio of 2:1 significantly decreased the cell viability with a synergistic effect (CI<1), except at the highest concentrations as indicated in Fig. 1C . A long-term colony formation assay in SKOV3 cells also verified that co-treatment with DHA and Cur prominently caused an irreversible cytotoxic effect compared to single DHA or Cur treatment ( Fig. 1D and E) . In addition, we also tested the cytotoxicity of DHA and/or Cur in other two ovarian cell lines, ES-2 and A2780. As showed in Fig.1C , G and I, there was different effects in different cell lines; the synergistic effect was the highest in SKOV3 cells, medium in ES-2 cells, and lowest in A2780 cells. We therefore used SKOV3 cells to explore the specific mechanisms.
Combination of DHA and Cur synergistically arrests cell cycle
To explore the reason underlying the decreased cell viability, SKOV3 cells were treated with DHA and/or Cur, and the cell cycle was detected. The results showed that DHA could induce a moderate accumulation in S and G2/M phases and a reduction in G0/G1 phase ( Fig.  2A and B) , whereas the proportion of SKOV3 cells in the S and G2/M phases was significantly increased after the combination treatment. To confirm these phenomena, WB analysis of S Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry 
Combined treatment of DHA and Cur synergistically promotes cell apoptosis independent of Caspase 3 activity
To explore the anti-tumor properties of combined DHA and Cur, cell apoptosis was measured. Results showed that DHA or Cur alone treatment caused limited apoptosis in SKOV3 cells, while co-treatment with DHA and Cur resulted in extensive apoptosis (Fig. 3A  and B) . WB analysis of the apoptotic-related proteins showed that the expression level of the pro-apoptotic protein Bax was nearly unchanged, while the activity of Bcl-2 was markedly decreased after treatment with combination of DHA and Cur, compared to single treatment and untreated controls (Fig. 3C) . Surprisingly, Caspase 3, a marker of late apoptosis, was not changed and the activity of it in the single drug or co-treatment groups was relatively lower than control (Fig. 3D) . Pre-treatment with the Caspase 3 inhibitor also did not show any observable cell apoptosis in any group (Fig. 3A) . These results suggest that cell apoptosis induced by DHA and/or Cur may be independent of Caspase 3 pathway.
DHA and Cur synergistically downregulates the expression and secretion of MK, a direct target of miR-124
MK is reported to be involved in various tumorigenesis and tumor development processes. To address the antitumor pharmacological mechanism of DHA and Cur against SKOV3 cells, MK levels were investigated. The results showed that the combination of 
Combination of DHA with Cur-induced SKOV3 cell apoptosis is modulated by miR-124-mediated MK degradation
We investigated whether the DHA + Cur-induced SKOV3 cell apoptosis are related to miR-124-mediated MK dysfunction. First, we explored cell apoptosis in MK deletion and addition conditions. As shown in Fig. 5A and B, si-MK3 had the most visible MK silencing effect; thus, we choose it for the next experiments. The results showed that knockdown of MK further aggravated apoptosis (Fig. 5C and D) , whereas the addition of exogenous cytokine of MK reversed it (Fig. 5E and F) . In addition, SKOV3 cells were pre-treated with miR-124 mimic and miR-124 inhibitor to mimic a miR-124 gain and loss of function, and then were further co-treated with DHA and Cur to explore the relationship between miR-124 and MK. The results showed that the group pre-treated with miR-124 mimic further decreased the expression of MK (Fig. 5G) , whereas miR-124 inhibitor partially overturned this phenomenon compared with control. Furthermore, overexpression of miR-124 mimic before co-treatment of DHA + Cur reduced cell vitality, and miR-124 inhibitor slightly reversed it (Fig. 5H) . The data suggest that DHA + Cur induced SKOV3 cell apoptosis was at least partially via miR-124 mediated MK degradation.
Combination of DHA with Cur synergistically inhibits tumor formation in vivo
To investigate whether the combination of DHA and Cur has the same elimination effect on tumors in vivo, a heterologous SKOV3 tumor model was established. DHA alone (30 mg/ kg), Cur alone (20 mg/kg), and DHA + Cur (30 mg/kg + 20 mg/kg) were administered by intraperitoneal injection. The cell proliferation in solid tumor was measured by Ki67. As shown in Fig. 6A and B, the suppression of cancer cell proliferation was exhibited more prominently in the combination group than in either the DHA or Cur alone group. In addition, the combined treatment of DHA and Cur significantly inhibited the tumor growth compared to control or single drug treatment (Fig. 6C, D, and E) . Moreover, the mean body weight of all drug-treated groups was hardly changed in comparison with the control group, which suggests that the combination of DHA + Cur may not cause serious adverse effects in vivo (Fig. 6F) .
Discussion
For the treatment of ovarian cancer, a standard recommendation is a primary chemotherapy followed by surgical resection [31] . This therapy, however, may be difficult for some patients with advanced ovarian carcinoma, with a greater incidence of poor prognosis. Therefore, novel therapeutic agents that specifically, efficiently, and safely treat this condition are needed. DHA and Cur are among the most popular nutritional supplements. DHA is available inexpensively and Cur supplements are currently available worldwide [32] . We therefore tentatively suggest that a combination of DHA and Cur, two active ingredients in Chinese herbs, might be an alternative for treatment of patient with ovarian cancer. Our results presented in this paper demonstrate that DHA and Cur synergistically aggravated the apoptosis of SKOV3 cells and might be involved in upregulation miR-124 targeting MK.
In this study, DHA and Cur alone inhibited the cell viability of SKOV3 cells in a doseand time-dependent manner; the combination treatment of DHA and Cur was more effective than either single agent, demonstrating a synergistic effect. As our data demonstrates, while DHA alone could more effectively arrest cell cycle at S and G2/M, Cur further potently induced cell apoptosis, and the combination of both contributed to a considerable decrease in cell viability. Previous studies revealed that DHA and Cur treatment alone delayed the growth of ovarian cancer, including a dose-dependent G2/M arrest [33, 34] . In addition, targeting the Bcl-2 family-mediated apoptosis components was an important mechanism for the antitumor activity of DHA in cancer cells, and Cur could potentiate the anticancer effect of chemotherapy for cell apoptosis [35, 36] . Consistent with previous reports, our results also indicated that elevated apoptosis in the co-treatment of DHA and Cur group Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry was accompanied by a decrease of Bcl-2. Nevertheless, the apoptosis induced by DHA, Cur or the DHA + Cur combination failed to activate Caspase 3. Pre-treatment with Caspase 3 inhibitor did not inhibit cell apoptosis in any group, indicating that the apoptotic pathway induced by DHA and Cur was not via activation of Caspase 3, and other apoptotic pathways may contribute to the cell apoptosis. As a biomarker in several clinical oncology settings, MK has already been proven to have utility for initial cancer screening and recurrence monitoring. Numerous studies have shown that miRNAs are aberrantly expressed with tumorigenesis, and many miRNAs are downregulated in ovarian cancer [37] , among which, miR-124 has been widely reported to function as a tumor suppressor by regulating cell proliferation, invasion and apoptosis. In our study, depletion of MK by siRNA further accelerated the apoptosis of SKOV3 cells, and exogenous addition overturned the phenomenon in the co-treatment group. Overexpression of miR-124, which was synergistically upregulated by DHA and Cur, also attenuated the expression of MK and caused decreased cell viability in SKOV3 cells. The miR-124 inhibitor, however, only slightly reversed the MK expression in mRNA level, and the protein level was nearly unchanged, which meant that other factors might be also involved in the regulation of MK in SKOV3 cells. In addition, our study also found that, when co-treatment with DHA and Cur, the MDR1 coding P-gp responsible for transporting a wide range of anticancer agents was also attenuated. Silencing of MK by siRNA and overexpression of miR-124 both caused a decrease of MDR1 (data not shown). Therefore, we tentatively put forward that the combination treatment of DHA and Cur may also have excellent anti-tumor properties in SKOV3 cells by destroying the P-gp function of excreting drugs, causing additional cytotoxicity. More importantly, compared to control and single drug treatment, the xenograft nude mice tumor model also demonstrated that co-treatment of DHA + Cur caused significant tumor retardation without any side-effects. These results indicated that DHA and Cur combination treatment was a safe therapeutic regimen.
In conclusion, our studies revealed that combination treatment with DHA and Cur synergistically exhibited prominent anti-tumor activity by inhibiting cell viability, arresting cell cycle and promoting cell apoptosis both in vitro and in vivo. The underlying molecular mechanisms might be through upregulation of miR-124 targeting MK for efficient cytotoxicity to SKOV3 cells. As both DHA and Cur are commercially available, therapeutically effect and most importantly, remarkably safe, it can be considered as a promising therapeutic strategy for ovarian cancer in the elderly.
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry
